Abou-Alfa GK et al. Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. ASCO 2021;Abstract 4069.
Abou-Alfa GK et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. ASCO 2022;Abstract 379.
Abou-Alfa GK et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid, June 6, 2022. Abstract
Bekaii-Saab TS et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. ASCO 2022;Abstract 519.
Cheng AL et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76(4):862-73. Abstract
Falkson SR et al. Biliary cancer brain metastases: A multi-institution case series with case reports. J Gastrointest Oncol 2022;13(2):822-32. Abstract
Goyal L et al. Updated results from the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. ASCO 2022;Abstract 4009.
Greten TF et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9(9):e002794. Abstract
He AR et al. Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the Phase 3 TOPAZ-1 study. ESMO GI 2022;Abstract O-1.
Israel MA et al. Comparative genomic analysis of intrahepatic cholangiocarcinoma: Biopsy type, ancestry, and testing patterns. Oncologist 2021;26(9):787-96. Abstract
Javel M et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gasteroenterol Hepatol 2021;6(10):803-15. Abstract
Kelley RK, Greten TF. Hepatocellular carcinoma – Origins and outcomes. N Engl J Med 2021;385(3):280-2. Abstract
Kelley RK et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2022;23(8):995-1008. Abstract
Kelley RK et al. Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors. ASCO 2022;Abstract TPS4173.
Kelley RK et al. Prevalence of germline mutations and homologous recombination deficiency (HRD) in a real-world biliary tract cancer (BTC) cohort. Gastrointestinal Cancers Symposium 2022;Abstract 476.
Kelley RK et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study. J Clin Oncol 2021;39(27):2991-3001. Abstract
Lim HY et al. Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348). Gastrointestinal Cancers Symposium 2022;Abstract 436.
Llovet JM et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7(1):6. Abstract
Llovet JM et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer 2022;3(4):386-401. Abstract
McCoon P et al. T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). ASCO 2021;Abstract 4087.
Melero I et al. Nivolumab (nivo) plus ipilimumab (ipi) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040. ESMO GI 2022;Abstract SO-12.
Meric-Bernstam F et al. Zanidatamab (ZW25) in HER2-positive biliary tract cancer (BTC): Results from a Phase I Study. ASCO GI 2021;Abstract 299.
Modi K et al. Multimodal profiling of biliary tract cancers to detect potentially actionable biomarkers and differences in immune signatures between subtypes. Gastrointestinal Cancers Symposium 2021;Abstract 4023.
Oh D-Y et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid, June 1, 2022. Abstract
Ohba A et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trail). ASCO 2022;Abstract 4006.
Pfister D et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592(7854):450-6. Abstract
Qin S et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma: Phase 3 KEYNOTE-394 study. Gastrointestinal Cancers Symposium 2022;Abstract 383.
Rimini M et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study. ESMO GI 2022;Abstract SO-14.
Sangro B et al. Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. ASCO 2022;Abstract 4074.
Silverman IM et al. Validation and characterization of FGFR2 rearrangements in cholangiocarcinoma with comprehensive genomic profiling. J Mole Diag 2022;24(4):351-64. Abstract
Subbiah V et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21(9):1223-43. Abstract
Valle JW et al. Biliary tract cancer. Lancet 2021;397(10272):428-44. Abstract
Vogel A et al. Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study. ESMO GI 2022;Abstract O-5.
Vogel A et al. Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202. ESMO GI 2022;Abstract O-2.
Xing R et al. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol 2021;12:783236. Abstract
Yau T et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomized, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23(1):77-90. Abstract
Zhu AX et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH2 mutation: The phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 2021;7(11):1669-77. Abstract